JPWO2022159984A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022159984A5
JPWO2022159984A5 JP2023544446A JP2023544446A JPWO2022159984A5 JP WO2022159984 A5 JPWO2022159984 A5 JP WO2022159984A5 JP 2023544446 A JP2023544446 A JP 2023544446A JP 2023544446 A JP2023544446 A JP 2023544446A JP WO2022159984 A5 JPWO2022159984 A5 JP WO2022159984A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504390A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/070326 external-priority patent/WO2022159984A1/en
Publication of JP2024504390A publication Critical patent/JP2024504390A/ja
Publication of JPWO2022159984A5 publication Critical patent/JPWO2022159984A5/ja
Pending legal-status Critical Current

Links

JP2023544446A 2021-01-22 2022-01-24 抗her-2/trop-2構築物及びその使用 Pending JP2024504390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163140638P 2021-01-22 2021-01-22
US63/140,638 2021-01-22
PCT/US2022/070326 WO2022159984A1 (en) 2021-01-22 2022-01-24 Anti-her-2/trop-2 constructs and uses thereof

Publications (2)

Publication Number Publication Date
JP2024504390A JP2024504390A (ja) 2024-01-31
JPWO2022159984A5 true JPWO2022159984A5 (enrdf_load_stackoverflow) 2025-02-03

Family

ID=80595406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544446A Pending JP2024504390A (ja) 2021-01-22 2022-01-24 抗her-2/trop-2構築物及びその使用

Country Status (6)

Country Link
US (1) US20240101717A1 (enrdf_load_stackoverflow)
EP (1) EP4281484A1 (enrdf_load_stackoverflow)
JP (1) JP2024504390A (enrdf_load_stackoverflow)
KR (1) KR20230147092A (enrdf_load_stackoverflow)
CN (1) CN116917326A (enrdf_load_stackoverflow)
WO (1) WO2022159984A1 (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024009292A (es) * 2022-01-26 2024-08-06 Biocytogen Pharmaceuticals Beijing Co Ltd Anticuerpos anti-her2/trop2 y usos de los mismos.
WO2024046455A1 (en) * 2022-09-01 2024-03-07 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Methods for preparing antibody-drug conjugates
WO2024206815A2 (en) * 2023-03-29 2024-10-03 Mythic Therapeutics, Inc. Trop2-binding proteins and uses thereof
WO2025072041A1 (en) * 2023-09-28 2025-04-03 Merck Sharp & Dohme Llc Use of an immunoconjugate for the treatment of non-small cell lung cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
DE3307869A1 (de) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3584486D1 (de) 1984-02-08 1991-11-28 Cetus Corp Toxinkonjugate.
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
DE69334351D1 (de) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetisches Bindeprotein für Tumormarker
US5698413A (en) 1993-05-05 1997-12-16 The United States Of America As Represented By The Department Of Health And Human Services Method of evaluating chemotherapeutic agents in vivo
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
ATE244758T1 (de) 1998-04-21 2003-07-15 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
AU2004316290C1 (en) 2003-11-06 2012-02-02 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
JP7274413B2 (ja) * 2016-09-23 2023-05-16 マレンゴ・セラピューティクス,インコーポレーテッド ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
TN2019000055A1 (en) * 2016-09-29 2020-07-15 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs and preparation methods thereof
EP3793600A4 (en) 2018-05-16 2022-05-11 Arbele Limited Composition of bispecific antibodies and method of use thereof
CN116745316A (zh) * 2020-09-04 2023-09-12 武田药品工业有限公司 具有人血清白蛋白结构域的受限条件激活结合蛋白构建体

Similar Documents

Publication Publication Date Title
JP7378474B2 (ja) 抗-4-1bb抗体およびその用途
KR101287777B1 (ko) 가용성 cea에 대한 내성을 가지는 약학적 조성물
US20090028859A1 (en) Bispecific antibodies that bind to vegf receptors
MX2010011955A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
TW201026325A (en) Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
JP7350740B2 (ja) Ildr2アンタゴニストおよびその組み合わせ
JP2010509931A5 (enrdf_load_stackoverflow)
JP2020522488A5 (enrdf_load_stackoverflow)
WO2023071676A1 (zh) 一种抗her2/抗pd-l1双功能抗体及其应用
JP2024001073A5 (enrdf_load_stackoverflow)
US20230071019A1 (en) Compositions and methods for reducing off-target toxicity of antibody drug conjugates
KR20230132544A (ko) 신규한 항-그렘린1 항체
JP2023036612A (ja) プレクチン1結合性抗体およびその使用
JP2024020436A5 (enrdf_load_stackoverflow)
CN114829405A (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
JPWO2022159984A5 (enrdf_load_stackoverflow)
WO2004003211A1 (en) Bispecific antibodies that bind to vegf receptors
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
KR20210031913A (ko) 항-인간 pd-l1 항체 및 그것의 용도
JPWO2022067262A5 (enrdf_load_stackoverflow)
JPWO2019212965A5 (enrdf_load_stackoverflow)
CN117500832A (zh) 抗her3抗体、含有该抗体的抗体药物缀合物及其用途
CN116284408A (zh) 结合人muc17的抗体、其制备方法及用途
JPWO2021247769A5 (enrdf_load_stackoverflow)
CN113329769A (zh) 具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物